cefilavancin (TD-1792) / R-Pharm, Theravance Biopharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cefilavancin (TD-1792) / R-Pharm, Theravance Biopharma
NCT00442832: TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

Completed
2
203
US
TD-1792, Vancomycin
Theravance Biopharma
Staphylococcal Skin Infection
05/07
05/07

Download Options